These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6668546)

  • 21. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of pentopril, a new orally active angiotensin-converting enzyme inhibitor, and its active metabolite in rats.
    Rakhit A; Kochak G; Dotson R; Tipnis V
    J Pharm Sci; 1985 Sep; 74(9):947-52. PubMed ID: 2999376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade.
    Constantine JW; Lebel W; Weeks R
    J Cardiovasc Pharmacol; 1984; 6(1):142-50. PubMed ID: 6199597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Terazosin kinetics after oral and intravenous doses.
    Patterson SE
    Clin Pharmacol Ther; 1985 Oct; 38(4):423-7. PubMed ID: 4042526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rest and exercise hemodynamic effects of sequential alpha-1-adrenoceptor (trimazosin) and beta-adrenoceptor (propranolol) antagonism in essential hypertension.
    Nelson GI; Silke B; Hussain M; Verma SP; Taylor SH
    Am Heart J; 1984 Jul; 108(1):124-31. PubMed ID: 6731261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man.
    Singleton W; Saxton CA; Hernandez J; Prichard BN
    J Cardiovasc Pharmacol; 1982; 4 Suppl 1():S145-51. PubMed ID: 6175830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.
    McNeil JJ; Anderson AE; Louis WJ; Morgan DJ
    Br J Clin Pharmacol; 1979; 8(Suppl 2):157S-161S. PubMed ID: 526397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure.
    Aronow WS; Danahy DT
    Am J Med; 1978 Jul; 65(1):155-60. PubMed ID: 356598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses.
    Edgar B; Regårdh CG; Lundborg P; Romare S; Nyberg G; Rönn O
    Biopharm Drug Dispos; 1987; 8(3):235-48. PubMed ID: 3593901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
    O'Connor PC; Arnold JM; Brown AN; Francis RJ; Finch MB; Galloway DB; Harron DW; McDevitt DG; Shanks RG
    Br J Clin Pharmacol; 1985 Mar; 19(3):319-27. PubMed ID: 2859047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the vasodilator trimazosin versus placebo on exercise performance in chronic left ventricular failure.
    Aronow WS; Greenfield RS; Alimadadian H; Danahy DT
    Am J Cardiol; 1977 Nov; 40(5):789-93. PubMed ID: 335867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human pharmacology of the methamphetamine stereoisomers.
    Mendelson J; Uemura N; Harris D; Nath RP; Fernandez E; Jacob P; Everhart ET; Jones RT
    Clin Pharmacol Ther; 2006 Oct; 80(4):403-20. PubMed ID: 17015058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biotransformation of urapidil: metabolites in serum and urine and their biological activity in vitro and in vivo.
    Zech K; Eltze M; Kilian U; Sanders KH; Kolassa N
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):180-96. PubMed ID: 6098228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of intravenous terazosin in hypertensive patients. A preliminary report.
    Cohen A
    Am J Med; 1986 May; 80(5B):86-93. PubMed ID: 2872814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.
    Csajka C; Buclin T; Fattinger K; Brunner HR; Biollaz J
    Clin Pharmacokinet; 2002; 41(2):137-52. PubMed ID: 11888333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-dose pharmacokinetics of labetalol in healthy young men.
    Nyberg G; Hansson R; Tietz F
    Acta Med Scand Suppl; 1982; 665():67-73. PubMed ID: 6961762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat.
    Caccia S; Muglia M; Mancinelli A; Garattini S
    Xenobiotica; 1983 Mar; 13(3):147-53. PubMed ID: 6613160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of alpha-adrenergic receptor blockade on coronary circulation in conscious dogs.
    Macho P; Hintze TH; Vatner SF
    Am J Physiol; 1982 Jul; 243(1):H94-8. PubMed ID: 6124131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics and metabolism of trazodone in man (author's transl)].
    Jauch R; Kopitar Z; Prox A; Zimmer A
    Arzneimittelforschung; 1976; 26(11):2084-9. PubMed ID: 1037253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery disease.
    Kern MJ; Horowitz JD; Ganz P; Gaspar J; Colucci WS; Lorell BH; Barry WH; Mudge GH
    J Am Coll Cardiol; 1985 Apr; 5(4):840-6. PubMed ID: 2857738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.